Effect of Okt3 in Steroid-Resistant Renal Transplant Rejection

PETRIE, JAMES J.B.; RIGBY, RUSSELL J.; HAWLEY, CARMEL M.; SURANYI, MICHAEL G.; Whitby, Michael; WALL, DARRYL; HARDIE, IAN R.

doi:10.1097/00007890-199502000-00007

Cited by 24 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most cases, a first rejection episode can be adequately treated with high-dose corticosteroids. However, in approximately 30% of the patients, the rejection episode cannot be reversed with corticosteroid therapy alone (2,8,10). In these cases of steroid resistance, the patient requires more rigorous therapy with antithymocyte globulin (ATG).…”

mentioning

confidence: 99%

Quantitative Polymerase Chain Reaction Profiling of Immunomarkers in Rejecting Kidney Allografts for Predicting Response to Steroid Treatment

Rekers

Bajema²,

Mallat³

et al. 2012

Transplantation

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Quantitative Polymerase Chain Reaction Profiling of Immunomarkers in Rejecting Kidney Allografts for Predicting Response to Steroid Treatment

Rekers

Bajema²,

Mallat³

et al. 2012

Transplantation

View full text Add to dashboard Cite

show abstract

“…Several studies have demon strated the greater effectiveness of this preparation in reversing acute rejection episodes when compared with corticosteroid therapy [7,10,13]. The Ortho Multicenter Transplant Study Group trial [13] showed that OKT3 reversed 94% of all acute renal allograft rejection epi sodes.…”

Section: Discussionmentioning

confidence: 99%

“…A powerful immuosuppressive agent, however, can be expected to have side effects and the use of OKT3 has been associated with infective complications [7,18], and other problems such as the cytokine release syndrome, nephrotoxicity, neurotoxicity and the development of antibodies to OKT3. The latter may preclude its further use.…”

Section: Discussionmentioning

confidence: 99%

OKT3 for the Treatment of Steroid-Resistant Acute Renal Allograft Rejection

Jagose

Bailey²,

Lynn³

et al. 1997

Nephron

View full text Add to dashboard Cite

OKT3 (Orthoclone) was first used in this unit on February 25, 1987. Up until March 31, 1996, 153 patients had a total of 163 transplants. Fifty of these patients who received 53 transplants (28 male, mean age 37.5 years, 48 cadaveric donors), were treated with OKT3 for steroid-resistant acute rejection. Forty-nine graft biopsies were undertaken and 47 showed acute rejection. In the other 4 episodes a clear-cut clinical and laboratory diagnosis of severe rejection was made. OKT3 (5 mg i.v.) was started at a median of 19 days following transplantation and was successful in reversing 43 of 51 (84%) episodes of steroid-resistant acute rejection. Of those treated, the patient and graft survival at 1 year was 86 and 69%, at 3 years 82 and 64% and at 5 years 79 and 61 %, respectively. Adverse effects were common. Four patients died from sepsis within the first 3 months after transplantation. OKT3 was effective in reversing 84% of steroid-resistant acute rejection episodes.

show abstract

“…The use of potent antibodies in renal transplant recipients has been linked with an increased mortality [3], and higher cyclosporine doses resulted in an increased rate of malignancies when compared with lower cyclosporine doses [16]. Furthermore, it is well established that infection rates increase with more aggressive immunosuppressive regimens [3,14,15,[17][18][19][20].The decision to choose a therapeutic or prophylactic regimen not only depends on the probabilities of the clinical outcome, but also on the patient's preference regarding this outcome. The patient's preferences for health outcomes can be explicitly assessed and expressed in quantitative terms known as utilities.…”

mentioning

confidence: 99%

“…Combinations of novel and traditional immunosuppressive drugs have certainly improved graft survival, but the advantages of a more efficacious immunosuppression with respect to transplant survival are troubled by an increased rate of opportunistic infections and/or malignancies [3][4][5][6][7][8][9][10][11][12][13][14][15]. The use of potent antibodies in renal transplant recipients has been linked with an increased mortality [3], and higher cyclosporine doses resulted in an increased rate of malignancies when compared with lower cyclosporine doses [16].…”

mentioning

confidence: 99%